From the Guidelines
The recommended dosing for Lokelma (sodium zirconium cyclosilicate) in treating hyperkalemia is 10 g TID (oral) for initial correction, followed by 5 g QOD to 15 g QD for maintenance. This dosing regimen is based on the most recent and highest quality study available, which provides guidance on the clinical management of hyperkalemia 1. The study highlights the importance of selective potassium binding and the role of Lokelma in facilitating the elimination of excess potassium through the feces.
Key Considerations for Lokelma Dosing
- The initial correction phase involves administering 10 g of Lokelma three times daily for up to 48 hours to rapidly lower potassium levels.
- Once potassium levels normalize, the maintenance phase begins, with a dose of 5 g every other day to 15 g once daily, adjusted based on serum potassium monitoring.
- Lokelma should be taken as an oral suspension, mixed with water, and consumed immediately to ensure optimal absorption.
- The medication's selective binding properties and lack of significant adverse effects, such as intestinal ischemia or colonic necrosis, make it a preferable option for managing hyperkalemia compared to other potassium-binding agents 1.
Monitoring and Adjustments
- Regular monitoring of serum potassium levels is crucial to guide ongoing therapy and prevent hypokalemia.
- Dose adjustments may be necessary for patients with severe hyperkalemia or those on dialysis, emphasizing the need for individualized treatment plans.
- The study's findings support the use of Lokelma as a safe and effective treatment for hyperkalemia, with a favorable adverse event profile compared to other available options 1.
From the FDA Drug Label
2.1 Recommended Dosage For initial treatment of hyperkalemia, the recommended dose of LOKELMA is 10 g administered three times a day for up to 48 hours. Administer LOKELMA orally as a suspension in water [see Dosage and Administration (2.3)]. For continued treatment, the recommended dose is 10 g once daily.
Monitor serum potassium and adjust the dose of LOKELMA based on the serum potassium level and desired target range. During maintenance treatment, up-titrate based on the serum potassium level at intervals of 1-week or longer and in increments of 5 g Decrease the dose of LOKELMA or discontinue if the serum potassium is below the desired target range. The recommended maintenance dose range is from 5 g every other day to 15 g daily.
The recommended dosing for Lokelma (sodium zirconium cyclosilicate) in treating hyperkalemia is:
- Initial treatment: 10 g three times a day for up to 48 hours
- Continued treatment: 10 g once daily
- Maintenance dose range: 5 g every other day to 15 g daily, adjusted based on serum potassium levels 2
From the Research
Lokelma Dosing for Hyperkalemia
- The recommended dosing for Lokelma (sodium zirconium cyclosilicate) in treating hyperkalemia is as follows:
- Studies have shown that Lokelma can lower serum potassium levels to within the normal range (3.5-5.0 mmol/L) within 48 hours of treatment 5, 3
- The efficacy and safety of Lokelma have been demonstrated in patients with hyperkalemia, including those with chronic kidney disease, diabetes, and heart failure 5, 6, 3, 4
- Lokelma has been shown to be generally well tolerated, with a similar tolerability profile to placebo 5, 3, 4
- The most common adverse events associated with Lokelma are gastrointestinal in nature, such as diarrhea 3, 4
Key Findings
- Lokelma has been shown to be effective in lowering serum potassium levels in patients with hyperkalemia 5, 6, 3, 4
- The medication has a favorable safety profile, with a low incidence of hypokalemia and other adverse events 5, 3, 4
- Lokelma can be used in patients with various underlying medical conditions, including chronic kidney disease, diabetes, and heart failure 5, 6, 3, 4